TVTX as reported
Travere Therapeutics, Inc. reported $591M of revenue over the trailing twelve months, +77% on the year before. 10 reported series are charted on this page, each one as filed.
$591M
Revenue, trailing twelve months · to Q2 2026 · +77% against the twelve months before
- Net Income
- −$43M
Net Income · −74% year on year · trailing twelve months to Q2 2026
- Op Margin
- −9.1%
Op Margin · trailing twelve months to Q2 2026
- EPS
- −$0.46
EPS · −77% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $591M | +77% | Q2 2026 |
| Net Income | −$43M | −74% | Q2 2026 |
| EPS | −$0.46 | −77% | Q2 2026 |
| Gross Margin | 99% | n/a | Q2 2026 |
| Op Margin | −9.1% | n/a | Q2 2026 |
| Net Margin | −8.0% | n/a | Q2 2026 |
| ROE | −85% | n/a | Q2 2026 |
| ROA | −7.5% | n/a | Q2 2026 |
| ROIC | −42% | n/a | Q4 2015 · 42 quarters behind |
| Free Cash Flow | −$318M | n/a | Q4 2024 · 6 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Travere Therapeutics, Inc. (TVTX) - Revenue & ProfitRevenue & ProfitTravere Therapeutics, Inc. (TVTX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com